[Federal Register Volume 87, Number 37 (Thursday, February 24, 2022)]
[Notices]
[Page 10389]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03901]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-956]


Bulk Manufacturer of Controlled Substances Application: Johnson 
Matthey Pharmaceutical Materials Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Johnson Matthey Pharmaceutical Materials Inc. has applied to 
be registered as a bulk manufacturer of basic class(es) of controlled 
substance(s). Refer to Supplemental Information listed below for 
further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before April 25, 2022. 
Such persons may also file a written request for a hearing on the 
application on or before April 25, 2022.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on November 5, 2021, Johnson Matthey Pharmaceutical 
Materials Inc., 25 Patton Road, Devens, Massachusetts 01434, applied to 
be registered as a bulk manufacturer of the following basic class(es) 
of controlled substance(s):

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Amphetamine.............................    1100  II
Methylphenidate.........................    1724  II
Nabilone................................    7379  II
Hydrocodone.............................    9193  II
Levorphanol.............................    9220  II
Thebaine................................    9333  II
Alfentanil..............................    9737  II
Remifentanil............................    9739  II
Sufentanil..............................    9740  II
------------------------------------------------------------------------

    The company plans to support its other manufacturing facilities 
located in West Deptford, New Jersey and Conshohocken, Pennsylvania 
with manufacturing and analytical testing. In reference to drug code 
9333 as bulk, the company plans to manufacture a Thebaine derivative 
for distribution to its customers. No other activities for these drug 
codes are authorized for this registration.

Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2022-03901 Filed 2-23-22; 8:45 am]
BILLING CODE P